Citigroup Inc. Has $46.51 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Citigroup Inc. lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 10.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 236,141 shares of the medical research company’s stock after purchasing an additional 22,788 shares during the quarter. Citigroup Inc. owned 0.46% of Charles River Laboratories International worth $46,513,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after buying an additional 163,056 shares during the last quarter. 1832 Asset Management L.P. purchased a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $33,053,000. Earnest Partners LLC boosted its position in Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after purchasing an additional 110,725 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Charles River Laboratories International by 73.6% in the second quarter. The Manufacturers Life Insurance Company now owns 239,913 shares of the medical research company’s stock worth $49,561,000 after purchasing an additional 101,732 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Barclays cut their price objective on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Baird R W cut Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. Finally, Bank of America lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their target price for the company from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and a consensus target price of $214.38.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $195.77 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The firm has a market cap of $10.01 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 5.01 and a beta of 1.38. The business’s fifty day moving average is $194.99 and its 200 day moving average is $205.65.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the company posted $2.72 EPS. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. Research analysts predict that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has authorized a share repurchase program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).